The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2020 | Current clinical practice for the diagnosis and treatment of CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the workshop at ERIC 2020 exploring the diagnosis and treatment of chronic lymphocytic leukemia (CLL) patients. In the workshop participants discussed the current clinical practice and key points of disease management. For example, most patients do not need to start treatment immediately after diagnosis. When patients do need to be treated, their biological profile will dictate whether they should have chemoimmunotherapy or novel agents. These will need to be reassessed if the patient experiences relapse. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
